By MEGGLE Excipients
Subscribe to Supplier
Subscribe to Supplier
Showing InhaLac® DPI range at PDD 2025 Istanbul
Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will be a prominent presence as a Silver Sponsor and exhibitor at the upcoming 10th Pulmonary Drug Delivery Workshop, returning to Istanbul.
The MEGGLE tabletop display in the Exhibition Zone of the Albert Long Hall on the Boğaziçi University Campus at Bebek will feature the company’s extensive range of sieved, milled and micronized InhaLac® lactose excipients.
There are now 13 grades in the InhaLac® range, with particle sizes precisely tailored to various dry powder inhaler (DPI) ranging from InhaLac® 70 with x50 particle size distribution (PSD) around 180-250 μm to the finest micronized InhaLac® 500 with particle sizes around 5-10 μm.
MEGGLE Team
The MEGGLE presence at PDD 2025 will be led by Business Development Manager for Inhalation Excipients Tristan Mul and Turkish Area Sales Manager Gürkan Altunok.
About MEGGLE
Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.
MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.
The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.
To learn more, visit: https://www.meggle-pharma.com/en/home.html
About PDD 2025
Established by Prof. Carsten Ehrhardt in 2013, the Pulmonary Drug Delivery Workshop (PDD) series aims to provide a space for meeting colleagues, discussing research and engaging in new collaborative efforts in the field of inhalation drug delivery.
The conference welcomes graduate students, postdocs and colleagues from academia and industry as well as government agencies.
PDD workshops alternate annually between Istanbul and Dublin to accommodate participants from Western, Central and Eastern Europe as well as from the Middle East and Africa.
The 10th Pulmonary Drug Delivery Workshop, PDD 2025, is a three -day event opening June 11 at the Albert Long Hall on the Boğaziçi University Campus at Bebek, north of Istanbul.
The event is organized by the PDD Organisation with further information at: https://www.pulmonarydrugdelivery.org
Resources
Click on MEGGLE Milled lactose for pulmonary and nasal drug delivery for further information.
Click on MEGGLE DPI technologies to view video.
PDD Workshop 2025 Venue: Albert Long Hall, Boğaziçi University, Bebek, Istanbul.
MEGGLE InhaLac® sieved, milled and micronized lactose-based excipients tailored to a wide range of Dry Powder Inhalation (DPI) applications.
Related Articles
